Abstract:Objective To evaluate the effect of risedronate on the healing of osteoporotic fracture in rats by relevant biomechanics.Methods Ninety healthy female SD rats aged 6 months were randomly divided into A,B,and C3 groups:normal control group (group A),ovariectomized model + femoral shaft fracture model + risedronate sodium.Treatment group (group B) and ovariectomized model + femoral shaft fracture model + saline gavage group (group C).Before the fracture modeling of each group,10 paw withdrawals were randomly selected,and the BMD value of the right femur fracture healing was detected.After the sacrificed rats,the right femoral stem was taken to detect the maximum load at the new epiphysis,the maximum load recovery rate.At the 3rd and 6th week after fracture modeling,rats in each group were tested again.Results In the modeling of fractures of rats in each group,the BMD value group and the intra-group comparison,before the modeling group,the P>0.05,the results were not statistically significant.In the comparison of mean values between groups and groups,the results were statistically significant(P<0.05).In the comparison between the biomechanical properties of the groups before and after the modeling of osteoporotic fractures in each group,the results were statistically significant(P<0.05),except in the maximum load recovery rate.In the comparison between groups B and C,the results were not statistically significant.In the maximum load,the results were not statistically significantin Group C.Conclusion The short-term application of risedronate sodium can promote the healing of osteoporotic fractures.
[1]Paskins Z,Jinks C,Mahmood W,et al.Public priorities for osteoporosis and fracture research:results from a general population survey[J].Archives of Osteoporosis,2017,12(1):45.
[2]Ralston SH,Fraser J.Diagnosis and management of osteoporosis[J].Practitioner,2015,10(12):15-19.
[3]Bijelic R,Milicevic S,Balaban J.Risk factors for osteoporosis in postmenopausal women[J].Med Arch,2017,71(1):25-28.
[4]Karunanayake AL,Pinidiyapathirage MJ,Wickremasinghe AR.Prevalence and predictors of osteoporosis in an urban Sri Lankan population[J].Int J Rheum Dis,2010,13(4):385-390.
[5]Wang D,Liu R,Zhu H,et al.Vita-min D receptor Fok I polymorphism is associated with low bone mineral density in postmenopausal women:a meta-analysis focused on populations in Asian countries[J].European Journal of Obstetrics & Gynecology and Reproductive Biology,2013,169(2):380-386.
[6]Carlberg C,Carsten.Endocrine functions of vitamin D[J].Mol Cell Endocrinol,2017,453(1):1-2.
[7]Carlberg C,Seuter S.The vitamin D receptor[J].Dermatol Clin,2007,25(4):515-523.
[8]Holick MF,Michael F,Vitamin D.Extraskelet al health[J].Rheum Dis Clin North Am,2012,38(1):141-160.
[9]Hossein-nezhad A,Holick MF.Optimize dietary intake of vitamin D:an epigenetic perspective[J].Curr Opin Clin Nutr Metab Care,2012,15(6):567-579.
[10]Holick MF.Vitamin D deficiency[J].N Engl J Med,2007,357(3):266-281.
[11]Kitazawa S,Kajimoto K,Kondo T,et al.Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter[J].J Cell Biochem,2003,89(4):771-777.
[12]Sabbagh Y,Carpenter TO,Demay MB.Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hyper-trophic chondrocytes[J].Proc Natl Acad Sci USA,2005,102(27):9637-9642.
[13]Donohue MM,Demay MB.Rickets in VDR null mice is sec-ondary to decreased apoptosis of hypertrophic chondrocytes[J].Endocrinology,2002,143(9):3691.
[14]van Driel M,van Leeuwen JPTM.Vitamin D endocrinology of bone mineralization[J].Mol Cell Endocrinol,2017,453(1):46-51.
[15]Song Y,Peng X,Porta A,et al.Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are differentially regulated by 1,25 dihydroxyvitamin D3 in the intestine and kidney of mice[J].Endocrinology,2003,144(9):3885-3894.
[16]Van Abel M,Hoenderop JG,van der Kemp AW,et al.Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection[J].Am J Physiol Gastrointest Liver Physiol,2003,285(1):G78.
[17]Tiosano D,Hadad S,Chen Z,et al.Calcium absorption,kinetics,bone density,and bone structure in patients with hereditary vita-min D-resistant rickets[J].J Clin Endocrinol Metab,2011,96(12):3701-3709.
[18]Triliana R,Lam NN,Sawyer RK,et al.Skeletal characterization of an osteoblast-specific vitamin D receptor transgenic (ObVDR-B6) mouse model[J].J Steroid Bio-chem Mol Biol,2016,164(1):331-336.
[19]Fretz JA,Zella LA,Kim S,et al.1,25-Dihy-droxyvitamin D3 regulates the expression of low-density lipo-protein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription[J].Mol Endocrinol,2006,20(9):2215-2230.
[20]何渝煦,魏庆中,熊启良,等.骨质疏松性骨折与骨密度关系的研究进展[J].中国骨质疏松杂志,2014(2):219-224.
[21]王琳,沈芸.骨质疏松性骨折预测方法的研究进展[J].中国骨质疏松杂志,2015,21(5):638-642.
[22]Solomon DH,Hochberg MC,Mogun H,et al.The relation between bisphosphonate use and non-union of fractures of the humerus in older adults[J].Osteoporosis International,2009,20(6):895-901.
[23]Kates SL,Ackertbicknell CL.How do bisphosphonates attect fracture healing[J].Injury-international Journal of the Care of the Injured,2016,47(Suppl 2):S65.
[24]Fu L,Tang T,Hao Y,et al.Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats[J].Acta Pharmacol Sin,2013,34(3):387-392.
[25]Goldhahn J,Féron J M,Kanis J,et al.Implications for fracture healing of current and new osteoporosis treatments:an ESCEO consensus paper[J].Calcified Tissue International,2012,90(5):343-353.
[26]Goldhahn J,Little D,Mitchell P,et al.Evidence for anti-osteoporosis therapy in acute fracture situations——recommendations of a multidisciplinary workshop of the international society for fracture repair[J].Bone,2010,46(2):267-271.
[27]Klop C,Gibsonsmith D,Elders PJM,et al.Anti-osteoporosis drug prescribing after hip fracture in the UK:2000—2010[J].Osteoporosis International,2015,26(7):1919-1928.
[28]Gillespie CW,Morin PE.Osteoporosis-related health services utilization following first hip fracture among a cohort of privately-insured women in the united states,20082014:an observational study[J].Journal of Bone & Mineral Research,2017,32(5):1052-1061.
[29]Hagino H,Endo N,Ito Y,et al.The risk of a second hip fracture in patients after their first hip fracture[J].Calcified Tissue International,2012,90(1):14-21.
[30]Iba K,Dohke T,Takada J,et al.Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years.[J].Journal of Orthopaedic Science Official Journal of the Japanese Orthopaedic Association,2018,23(1):127.
[31]Hughes DE,Wright KR,Uy HL,et al.Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo[J].Journal of Bone & Mineral Research,1995,10(10):1478-1487.
[32]Jobke B,Milovanovic P,Amling M,et al.Bisphosphonate-osteoclasts:changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients[J].Bone,2014,59(59):37-43.
[33]Plotkin LI,Weinstein RS,Parfitt AM,et al.Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin[J].J Clin Invest,1999,104(10):1363-1374.
[34]Follet H,Li J,Phipps RJ,et al.Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading[J].Bone,2007,40(4):1172-1177.
[35]Matos MA,Tannuri U,Guarniero R.The effect of zoledronate during bone healing[J].Journal of Orthopaedics & Traumatology Official Journal of the Italian Society of Orthopaedics & Traumatology,2010,11(1):7-12.
[36]Amanat N,Mcdonald M,Godfrey C,et al.Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair?[J].Journal of Bone & Mineral Research,2007,22(6):867-876.
[37]Sigurdsen U,Reikeras O,Utvag SE.The influence of compression on the healing of experimental tibial fractures[J].Injuryinternational Journal of the Care of the Injured,2011,42(10):1152-1156.